VaxEquity Ltd, founded in 2020 by Professor Robin Shattock, is charting new territories in the biotechnology space with its pioneering self-amplifying RNA (saRNA) platform. The company's slogan, "Delivering the potential of self-amplifying RNA (saRNA) therapeutics and vaccines," succinctly captures its mission to revolutionize the delivery and efficacy of RNA vaccines.
By employing saRNA technology, VaxEquity Ltd enhances protein expression and offers significant advantages in terms of tolerability, slow-release characteristics, and thermostability. This innovative approach aims to address and overcome the current limitations faced by traditional RNA solutions, with the modified saRNA fine-tuning immune responses to achieve optimal results.
Helmed by a world-class team, VaxEquity Ltd leverages its flexible platform to swiftly design, develop, and scale a diverse pipeline of RNA assets. As the company continues to develop its offerings, it presents a compelling opportunity for investors keen on transformative biotech solutions.
